Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ribociclib
Find trials that include:  Any drugs shown
Results 1-13 of 13 for your search:
Start Over
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Age: 18 to 59
Trial IDs: CLEE011E2301, NCI-2014-02508, NCT02278120
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.
Phase: Phase III
Type: Treatment
Age: 18 and over, postmenopausal
Trial IDs: CLEE011F2301, NCI-2015-01088, NCT02422615
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162X2114, NCI-2013-01329, NCT01781572
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2106, NCI-2013-01630, NCT01857193
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2107, NCI-2014-00139, NCT01872260
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2108, NCI-2014-01570, NCT02088684
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011X2110C, NCI-2015-01657, NCT02292550
Ribociclib, Docetaxel. and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 145515, NCI-2015-01797, 15-15745, CLEE011XUS07T, NCI-2015-01701, NCT02494921
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLGX818X2109, NCI-2015-00412, NCT02159066
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011XUS03, NCI-2014-02068, NCT02187783
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Phase: Phase II
Type: Treatment
Age: 15 and over
Trial IDs: CLEE011X2201, NCI-2014-02525, 2014-000428-12, NCT02300987
Ribociclib in Treating Patients with Advanced Neuroendocrine Tumors of Foregut Origin
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0371, NCI-2015-01017, NCT02420691
Ribociclib and Gemcitabine Hydrochloride in Treating Patients with Advanced Solid Tumors or Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 262914, NCI-2015-00280, NCT02414724
Start Over